Overview

Bioequivalence Study of Two Formulations of Perindopril 4 mg Tablet Under Fasting Condition

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to find out whether the bioavailability of PT Dexa Medica's formulation of 4 mg perindopril tert-butylamine tablets was equivalent to that of the innovator's product (Prexum® 4 mg, Servier).
Phase:
N/A
Details
Lead Sponsor:
Dexa Medica Group
Treatments:
Angiotensin-Converting Enzyme Inhibitors
Perindopril